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Oscar Campuzano, PHD,yzx Ramon Brugada, MD, PHDyzxSEE PAGE 1976I n 1992, when Pedro and Josep Brugada publishedtheir seminal work on a new association of sud-den cardiac death (SCD) with an electrocardio-
graphic (ECG) pattern of right bundle branch block
and persistent ST-segment elevation in leads V1
through V3, they presented a cohort of 8 patients
(1). In 1997, Nademanee et al. (2) proved that this ECG
pattern was also responsible for sudden unexplained
death syndrome in South East Asia, a syndrome that
has curtailed the lives of young individuals for ge-
nerations in that area. Thus, what was depicted as a
scientiﬁc curiosity in 1992 is now known as Brugada
syndrome (BrS) and explains an important percen-
tage of deaths previously classiﬁed as idiopathic
ventricular ﬁbrillation, sudden unexplained death
syndrome, or sudden infant death syndrome (3).
In the past 2 decades, thanks to the progress in the
development of powerful sequencing tools, the ge-
netic understanding of this disease has been slowly,
but steadily, advancing. Currently, w25% of all clin-
ically diagnosed cases of BrS carry a pathogenic
variant in the SCN5A gene, making this the most
prevalent gene associated with this entity. Patho-
genic variants in 17 other genes have also been asso-
ciated with the disease, although all together, these
represent only an additional 5% of diagnosed cases.
As a consequence, nearly 70% of BrS cases remain
genetically undiagnosed after comprehensive screen-
ing of all associated genes known to date (3).*Editorials published in the Journal of the American College of Cardiology
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studies and consensus documents have established
guidelines for diagnosis, risk stratiﬁcation, and care
of this lethal disease, providing data to the medical
community regarding the value of ECG lead location
and provocation tests in the diagnosis, the value of
electrophysiological studies and noninvasive param-
eters in risk stratiﬁcation, and the value of drugs,
devices, and interventional strategies in preventing
recurrence of events (3).
Among scientists and clinicians in the ﬁeld, 2
controversies regarding BrS still remain: ﬁrst, a
pathophysiological argument on whether the disease
substrate is a disorder of repolarization or of depo-
larization and, second, a critical clinical matter
referring to how to manage the asymptomatic patient,
including whether to perform an EP study for risk
stratiﬁcation. The paper by Nademanee et al. (4) in
this issue of the Journal provides new information
and updates on both issues.The repolarization hypothesis claims that genetic
variants will cause a loss of equilibrium INa and Ito in
phase 1 of the cardiac action potential in favor of the
transient outward potassium current. This current
alteration can be better seen in the right ventricular
outﬂow tract (RVOT) as it seems that this is the area
where the equilibrium is more critical. This disequi-
librium will generate a shortening of the sub-
epicardial action potential, with elevation of the
ST-segment in the right precordial leads, and cause
a susceptibility to phase 2 re-entry. Evidence of this
hypothesis has been shown in a canine right ven-
tricular wedge model (5). In human BrS studies, albeit
limited to a few cases, these repolarization disparities
have yet to be demonstrated (6).
The depolarization hypothesis suggests that the
substrate for arrhythmogenicity is a right ventricular
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1988conduction delay (5). Evidence of the depolarization
hypothesis has been accumulating in the past several
years. Abnormal late potentials in the free wall of the
RVOT epicardium were recorded by Nagase et al. (7)
in patients with BrS in 2002. In 2005, Coronel et al.
(6) provided direct human evidence of conduction
delay caused by interstitial ﬁbrosis, without trans-
mural repolarization differences, in an explanted
heart from a patient with BrS (6). Similarly, a SCN5A
knockout animal model has shown increased ﬁbrosis,
which becomes more severe in aging males, affecting
all cardiac regions, but especially the right ventricle
(8). Finally, some of the strongest evidence favoring
the depolarization hypothesis became available in
2011, when Nademanee et al. (9) performed electro-
anatomic mapping in 9 symptomatic BrS patients.
They showed abnormal low-voltage fractionated
ventricular electrocardiogram in the anterior RVOT
epicardium, with marked delayed conduction times.
Catheter ablation at this site resulted in the disap-
pearance of the Brugada ECG pattern and prevention
of both spontaneous and induced ventricular tachy-
cardia/ventricular ﬁbrillation episodes, suggesting
that delayed depolarization was the most likely un-
derlying electrophysiological mechanism.
Nademanee et al. (4) bring new evidence favoring
the depolarization hypothesis, with histopathological
and expression pattern changes, which increases our
understanding of the conduction alterations under-
lying the disease. They performed genetic and
immunohistological analyses of 6 forensic samples
from family members who were affected with BrS.
They also performed the same experiments in 6 biopsy
samples of patients with a diagnosis of BrS. Notwith-
standing the limitations of a very limited genetic
analysis, only performing a screening of SCN5A, and
the inability to conﬁrm the potentially pathogenic
variant in the forensic sample, it could be assumed
that the sudden death victims died of the same familial
disease. Of 11 samples analyzed, they identiﬁed 3 ge-
netic variants potentially associated with the disease
(p.Ser528Cys, p.Leu846Arg, and p.Leu1462Gln) in
relatives of 3 different families. Two variants are novel
(p.Ser528Cys and p.Leu1462Gln), whereas p.L846R_
SCN5A (p.Leu846Arg) was reported as pathogenic
(CM119205) and associated with ventricular ﬁbrilla-
tion (10). In silico analyses predicted all 3 variants to
be deleterious/pathogenic, supporting their potential
pathogenic role. Hence, these variants could be the
most plausible cause of BrS despite the fact that
neither in vitro nor in vivo analysis was performed.
Most interestingly, irrespective of whether a genetic
variant was detected, the immunohistological anal-
ysis showed an increase in epicardial collagen andﬁbrosis and a decrease in gap junction Connexin43
expression, especially in the RVOT area.
Thus, we know that BrS is an inherited disease,
mainly associated with cardiac channelopathies, that
typically causes SCD in the third to fourth decades of
life. From the data presented, symptomatic patients,
with or without an identiﬁed pathogenic genetic
variant, may present with ﬁbrosis and an altered
pattern of expression of connexin-43. The murine
animal model indicates that the genetic background
is more than simply a bystander, and it probably
plays a causative role in the histological phenotype.
Putting it all together, we could assume that the
histological changes are genetically related morpho-
logical defects that appear later in life and trigger
malignant arrhythmias. This could be a very rea-
sonable explanation linking genetics, age, ﬁbrosis,
and symptoms. Because histological alterations were
observed in the post-mortem cases as well as in the
biopsy specimens of symptomatic patients, histo-
logical and immunohistochemical analyses could
become new tools for the diagnosis of BrS, as the
authors claim. However, a key question comes to
mind: do asymptomatic patients with a type 1 elec-
trocardiogram present also with morphological de-
fects? If they do, the test will be of no use for
deﬁning risk, but it will reinforce the hypothesis that
the ECG alteration is caused by conduction delay. If
they do not show the changes, the test could be
potentially used even for risk stratiﬁcation, but the
ST-segment elevation will not be a sign of histologi-
cal disease, and the repolarization hypothesis will
regain strength. In favor of this latter argument is the
fact that the electrocardiogram normalizes very
quickly in a large percentage of patients, which is
difﬁcult to comprehend if the ECG pattern is caused
purely by a ﬁxed structural disease and not by
continuously changing ionic current equilibriums.
The paper by Nademanee et al. (4) sheds some
light on the repolarization or depolarization contro-
versy and in addition provides new evidence of the
ablation approach to symptomatic patients with BrS.
RVOT ablation makes the ST-segment elevation
disappear and reduces symptoms in symptomatic
patients.
It is not farfetched to suggest that ablation ther-
apy will rapidly become another controversial issue
in the asymptomatic patient. Let us not forget that
all symptomatic individuals have remained asymp-
tomatic for many years until their ﬁrst symptom. We
are currently at the learning curve of ablation in
BrS, and it is probably too soon to propose RVOT
ablation for the asymptomatic patient. With more
experience, it will be difﬁcult to argue against
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1989eliminating this dreaded ECG pattern. Although
normalization of the electrocardiogram by ablation
can become a reassuring exercise, only time will tell
whether the risk of sudden death will be completely
eliminated.REPRINT REQUESTS AND CORRESPONDENCE: Dr. Ramon
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